Safety and Tolerability of WVE-120101 in Patients With Huntington's Disease

NCT03225833 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

61

Enrollment

INDUSTRY

Sponsor class

Stopped Lack of Efficacy

Conditions

Huntington's Disease

Interventions

DRUG: WVE-120101
DRUG: Placebo

Sponsor

Wave Life Sciences Ltd.